Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,031 public trials 2,028 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, Not Recruiting

A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

NCT03319667

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Investigational Site Number: 8400006 Fort Myers, Florida, United States
  • Investigational Site Number: 8400004 St. Petersburg, Florida, United States
  • Investigational Site Number: 8400007 Kansas City, Missouri, United States
  • Investigational Site Number: 8400005 Nashville, Tennessee, United States
View all 104 locations
View Trial Details
Active, Not Recruiting

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

NCT01886872

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +17 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
View all 940 locations
View Trial Details
Active, Not Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

NCT03007147

Conditions
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Burkitt Lymphoma, +24 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • USA Health Strada Patient Care Center Mobile, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
View all 226 locations
View Trial Details
Active, Not Recruiting

Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

NCT03057795

Conditions
Classic Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Hodgkin Disease, +9 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Mayo Clinic in Rochester Rochester, Minnesota, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details
Active, Not Recruiting

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

NCT03913949

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +17 more
Locations
  • Anhui Procincial hospital Hefei, Anhui, China
  • Henan Provincial Oncology Hospital Zhengzhou, Henan, China
  • Zhongnan Hospital of Wuhan University Wuhan, Hubei, China
  • Blood Diseases Hospital Chinese Academy of Medical Sciences Tianjin, Tianjin Municipality, China
View Trial Details
Active, Not Recruiting

A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain

NCT06125795

Conditions
Behavior, Chronic Disease, Chronic Lymphocytic Leukemia, +19 more
Locations
  • HUA - Txagorritxu /ID# 258263 Vitoria-Gasteiz, Alava, Spain
  • Sant Joan de Deu de Manresa /ID# 258266 Manresa, Barcelona, Spain
  • Hospital Universitari Mútua Terrassa /ID# 258267 Terrassa, Barcelona, Spain
  • Hospital Jerez De La Frontera /ID# 258282 Jerez de la Frontera, Cadiz, Spain
View all 25 locations
View Trial Details
Active, Not Recruiting

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

NCT06035497

Conditions
Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +26 more
Locations
  • Local Institution - 0031 Anjo-shi, Aichi-ken, Japan
  • Local Institution - 0011 Nagoya, Aichi-ken, Japan
  • Local Institution - 0024 Toyohashi, Aichi-ken, Japan
  • Local Institution - 0017 Kamogawa, Chiba, Japan
View all 40 locations
View Trial Details

Related conditions